Results 71 to 80 of about 20,731 (163)

Effectiveness of empiric aztreonam compared to other beta-lactams for treatment of Pseudomonas aeruginosa infections

Infection and Drug Resistance, 2018
Michael Hogan,1 Mary Barna Bridgeman,1 Gee Hee Min,1 Deepali Dixit,1 Patrick J Bridgeman,1 Navaneeth Narayanan1,2 1Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA; 2Division of ...
Hogan M, Bridgeman MB, Min GH, Dixit D, Bridgeman PJ, Narayanan N   +5 more
doaj  

Aztreonam.

Indian pediatrics, 2006
Aztreonam belongs to the monobactam group of naturally occurring antibiotic compounds characterized by a monocycling ring structure. Aztreonam is the first monobactam that has been approved for use in pediatric medicine by US FDA in the year 1998.
Seema, Kapoor, Geeta, Gathwala
openaire   +1 more source

Combination Therapy for OXA-48 Carbapenemase-Producing Klebsiella Pneumoniae Bloodstream Infections in Premature Infant: A Case Report and Literature Review

Infection and Drug Resistance
Yiyu Chen,1 Chuxuan Fang,1 Jun Luo,1 Xueling Pan,2 Zongyan Gao,3 Shuangyi Tang,1 Meng Li4– 6 1Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 2Newborn ICU, Guigang ...
Chen Y, Fang C, Luo J, Pan X, Gao Z, Tang S, Li M   +6 more
doaj  

<i>In vitro</i> activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan. [PDF]

JAC Antimicrob Resist
Yanagihara K, Tateda K, Doi Y, Takahashi S, Ohge H, Itahashi K, Okade H, Mikamo H.   +7 more
europepmc   +1 more source

In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021-2022). [PDF]

J Antimicrob Chemother
Yang Q, Tuon FF, Shah S, Kamat S, Mohamed N, Stone GG, Perez KK, Cantón R.   +7 more
europepmc   +1 more source

<i>In vitro</i> activity of aztreonam-nacubactam and cefepime-nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021-2023. [PDF]

JAC Antimicrob Resist
Karlowsky JA, Estabrook M, Suzuki E, Shimizu A, Okade H.   +4 more
europepmc   +1 more source

Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021. [PDF]

Emerg Infect Dis
Long T, Lovey A, Sanborn L, Zhao Y, Bulman ZP, Lin YT, Chen L.   +6 more
europepmc   +1 more source

Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales. [PDF]

J Clin Microbiol
Bhatnagar AS, Harris H, Jacobs E, Bumpus-White P, Balbuena R, Stambaugh H, Crayton K, Haynie J, Quintero Ilutsik J, Longo C, Bergman Y, Singh S, Murray M, Sabour S, Robinson ML, Machado M-J, Simner PJ.   +16 more
europepmc   +1 more source

Combination Therapy with Ceftazidime-Avibactam, Aztreonam, and Topical Polymyxin B for NDM-Producing <i>Klebsiella pneumoniae</i> CNS Infection: A Case Report. [PDF]

Infect Drug Resist
Qi G, Cong W, Zhang M, Wang S, Bai Z, Li B, Chen H.   +6 more
europepmc   +1 more source

Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens. [PDF]

Ann Med Surg (Lond)
Kumar D, Kaur N, Surender, Aman S, Bibi A.   +4 more
europepmc   +1 more source